Genetic drivers shape TREM2-dependent myeloid responses and glioblastoma progression
- 1University of Texas Health Science Center at Houston
Abstract
Glioblastoma (GBM) is characterized by a heterogeneous, myeloid-enriched, and highly immunosuppressive microenvironment. TREM2 regulates microglial and macrophage functions, but its role in GBM remains unclear. We investigated whether genetic drivers determine the effects of TREM2 using de novo and orthotopic transplantable murine models of Nf1-silenced/Ras-driven and PDGFB-driven GBM. To this end, we combined immune profiling, functional assays, secretome analysis, and single-cell RNA sequencing with bone marrow chimeras and conditional Trem2 deletion strategies. Trem2 deficiency prolonged survival and reduced tumor burden in Nf1-silenced/Ras-driven GBM, whereas it increased tumor burden without affecting survival in PDGFB-driven GBM. These different outcomes were accompanied by distinct changes in myeloid composition and soluble mediators. TREM2 was required for bone marrow-derived macrophage migration and microglial process extension towards Ras-derived, but not PDGFB-derived, tumor-conditioned medium. In contrast, both models showed impaired microglial efferocytosis. Single-cell RNA sequencing analysis of Nf1-silenced GBM showed that Trem2 loss shifted myeloid cells from disease-associated, pro-inflammatory states to a more homeostatic state. Bone marrow chimeras supported a tumor-promoting role for TREM2 in microglia, rather than infiltrating myeloid cells in Ras-driven GBM. In addition, conditional deletion of Trem2 before tumor implantation prolonged survival, whereas deletion after tumor establishment did not. These findings identify genetic context and timing of TREM2 activity as determinants of its effects on GBM progression, highlighting driver-dependent myeloid responses as considerations for developing TREM2-directed therapies in glioblastoma.
Related
- MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression in mice
- Cultural and social drivers of human genetic variation
- GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells
- Dynamic hybrid-hydrogel lung models decouple matrix composition, stiffness, and fibroblast conditioning to define distinct drivers of fibrotic progression
- Peptide-mediated inhibition of aberrant chaperone-mediated autophagy in pericytes prevents glioblastoma progression through MAPT/tau secretion
BibTeX
@misc{peshoff2026genetic,
title = {{Genetic drivers shape TREM2-dependent myeloid responses and glioblastoma progression}},
author = {M. M. Peshoff and T. M. Joshi and D. D'Souza and D. Kleidonas and M. Akter and A. Cieslukowski and J. Sepulveda and J. Wu and D. Hambardzumyan and L.-J. Wu},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.26.759860},
url = {https://www.biorxiv.org/content/10.64898/2026.10.26.759860v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Genetic drivers shape TREM2-dependent myeloid responses and glioblastoma progression
AU - M. M. Peshoff
AU - T. M. Joshi
AU - D. D'Souza
AU - D. Kleidonas
AU - M. Akter
AU - A. Cieslukowski
AU - J. Sepulveda
AU - J. Wu
AU - D. Hambardzumyan
AU - L.-J. Wu
PY - 2026
DA - 2026/10/26
PB - bioRxiv
DO - 10.64898/2026.10.26.759860
UR - https://www.biorxiv.org/content/10.64898/2026.10.26.759860v1
AB - Glioblastoma (GBM) is characterized by a heterogeneous, myeloid-enriched, and highly immunosuppressive microenvironment. TREM2 regulates microglial and macrophage functions, but its role in GBM remains unclear. We investigated whether genetic drivers determine the effects of TREM2 using de novo and orthotopic transplantable murine models of Nf1-silenced/Ras-driven and PDGFB-driven GBM. To this end, we combined immune profiling, functional assays, secretome analysis, and single-cell RNA sequencing with bone marrow chimeras and conditional Trem2 deletion strategies. Trem2 deficiency prolonged survival and reduced tumor burden in Nf1-silenced/Ras-driven GBM, whereas it increased tumor burden without affecting survival in PDGFB-driven GBM. These different outcomes were accompanied by distinct changes in myeloid composition and soluble mediators. TREM2 was required for bone marrow-derived macrophage migration and microglial process extension towards Ras-derived, but not PDGFB-derived, tumor-conditioned medium. In contrast, both models showed impaired microglial efferocytosis. Single-cell RNA sequencing analysis of Nf1-silenced GBM showed that Trem2 loss shifted myeloid cells from disease-associated, pro-inflammatory states to a more homeostatic state. Bone marrow chimeras supported a tumor-promoting role for TREM2 in microglia, rather than infiltrating myeloid cells in Ras-driven GBM. In addition, conditional deletion of Trem2 before tumor implantation prolonged survival, whereas deletion after tumor establishment did not. These findings identify genetic context and timing of TREM2 activity as determinants of its effects on GBM progression, highlighting driver-dependent myeloid responses as considerations for developing TREM2-directed therapies in glioblastoma.
ER -